CTMX CytomX Therapeutics Inc

$CTMX The criticism overlooks the very purpose of PROBODY technology. Yes, EpCAM is also expressed on healthy cells, but that’s exactly why the masking technology was developed: the drug is designed to be activated by tumor-associated proteases within the tumor microenvironment. Varseta-M should therefore not be equated with previous, unmasked EpCAM ADCs. The assumption that AIBW dosing automatically reduces efficacy is also unproven. The upcoming clinical data will be decisive. $CTMX

$CTMX Premarket activity has intensified recently. It is time for CTMX to turn around with data readouts approaching...

$CTMX I expect an announcement on November 4 that the Q3 ER is scheduled for November 16. Based on my medical knowledge, the mOS data from the dose escalation and expansion cohorts should be available by then. Hopefully, we’ll also get the mPFS data from the optimization cohorts. I just hope the damned management finally gives us some meaningful trial updates. The stock price has been steadily declining ever since the last update. It's so frustrating. I continue to believe CX2051 alone will deliver a mOS of ~14 months, roughly double that of currently available treatments for 3 line+ patients.

$CTMX Don’t be frustrated if we still don’t have mature mOS and mPFS data by mid-November. This is truly great news!

$CTMX every other e/r this year has been a Thursday aside from the initial data in March. I wouldn’t read too much into it. Not sure we get data this week, but there’s only 8 weeks left til year end, so it won’t be a terribly long wait.

$CTMX Imminent Catalysts for Varseta-M (CTMX) Rather than a competitor stealing the spotlight at ESMO, the most imminent clinical catalyst for end-line CRC is actually CytomX itself. The company is on track to deliver its updated Phase 1 monotherapy and dose-optimization data by the end of 2026. These impending results will finalize the monotherapy dose selection ahead of their scheduled FDA alignment and planned registrational trial kickoff in the first half of 2027. [1, 2, 3](AI)

$CTMX I also don’t think we’ll get any data next week. The big fish usually know when something is brewing. With such a high short interest, some of them would’ve probably started covering already if data were coming soon.

$CTMX | CytomX Therapeutics Announces November Investor Conferences November 2, 2026 CytomX Therapeutics, a leader in masked, conditionally activated biologics, announced that its management team will participate in two investor conferences this November: Guggenheim 3rd Annual Healthcare Innovation Conference • Date: Monday, November 9, 2026 • Fireside chat: 3:30 p.m. ET • Location: Boston, MA Jefferies Global Healthcare Conference • Date: Wednesday, November 18, 2026 • Fireside chat: 8:30 a.m. GMT • Location: London, UK

$CTMX notice how they said its a registration trial. They didn’t say it was going to a P2. Obviously, they are talking to the FDA about a pathway to AA considering they have FTD Wow they could just jump right to a P3. This Blockbuster drug could be APPROVED end of next year!!

$CTMX Quarterly results on November 5. No new data announced here. I’m hoping for mid-November in Barcelona. POC defended. I think we have a bottom. God willing.

$CTMX Pleasant to see it hold the line somewhat despite the brazen 10k $2 puts for Nov 26

$CTMX They’re not even close to done. There will be positive movement with the Varseta-M (CX-2051) Phase 1 data before year’s end.

$CTMX that was an ugly sell off on volume. Someone sizable exiting a position? Trimmed my position back to just enough to stay interested this am. Made $800 😂

$CTMX according to the data %83 going our way but temperature are spot on fort this time of year

$CTMX open label trial.. highest short % ever... 20%. Whats happening. Only 8 trial sites involved.

$CTMX It sucks but no worse then any other stock in this market. Good numbers will remove our pain. I believe and hold. 😎